D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic

Research output: Book/Report › Report › Research

Standard

D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. / Vogt, Henrik; Gaillard, Maxence; Green, Sara.

CORDIS EU research results, 2023. 79 p.

Research output: Book/Report › Report › Research

Harvard

Vogt, H, Gaillard, M & Green, S 2023, D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. CORDIS EU research results. <https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5f0af0357&appId=PPGMS>

APA

Vogt, H., Gaillard, M., & Green, S. (2023). D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. CORDIS EU research results. https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5f0af0357&appId=PPGMS

Vancouver

Vogt H, Gaillard M, Green S. D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. CORDIS EU research results, 2023. 79 p.

Author

Vogt, Henrik ; Gaillard, Maxence ; Green, Sara. / D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic. CORDIS EU research results, 2023. 79 p.

Bibtex

@book{adb1ff6d16be40318d43ce4ebf853f5c,
title = "D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic",
abstract = "Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kindof amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCsin PM, and as a contribution to methodological development in health technology more generally.",
author = "Henrik Vogt and Maxence Gaillard and Sara Green",
year = "2023",
language = "English",
publisher = "CORDIS EU research results",

}

RIS

TY - RPRT

T1 - D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic

AU - Vogt, Henrik

AU - Gaillard, Maxence

AU - Green, Sara

PY - 2023

Y1 - 2023

N2 - Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kindof amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCsin PM, and as a contribution to methodological development in health technology more generally.

AB - Organoids and organ-on-chip (OoC) are new and emerging technologies (NESTs) that are promised to bring great improvements to clinical practice in the form of personalized or precision medicine (PM). “Traditional” health technology assessments (HTAs) have in the past been focused on assessing the clinical evidence for technologies that already exist and have been studied in trials, but such a methodology runs into problems when assessing technologies that so far mostly exist as visions for the future. This takes another kindof amended health technology assessment method. In this report we develop such a technology assessment method for assessing organoids and OoCs as emerging technologies used directly in patient management in the clinic. We search for and review a heterogeneous literature on how to assess NESTs and scientific visions, extract from this literature methodological elements that suit our purpose and add fitfor-purpose elements that we could not find in the literature. The developed vision assessment method is both intended as for the next (D2.4) HYBRIDA report, where we apply it to assess visions for clinical applications of organoids and OoCsin PM, and as a contribution to methodological development in health technology more generally.

UR - https://cordis.europa.eu/project/id/101006012/results

M3 - Report

BT - D2.3. Adaptation of health technology assessment (HTA) to evaluate organoids and organ-on-a-chip as emerging technologies in the clinic

PB - CORDIS EU research results

ER -

ID: 340687136